AUSTIN, Texas–(BUSINESS WIRE)–TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the first quarter ended March 31, 2020, as well as provided a business update on recent corporate and clinical developments. The Company will discuss the clinical, corporate and financial highlights on a conference call and live webcast, scheduled today, Thursday, May 14, 2020 at 5:00pm EDT.

“This has been another quarter of major accomplishment for TFF Pharmaceuticals,” said Glenn Mattes, President and CEO of TFF Pharmaceuticals. “We’ve maintained the clinical momentum behind our two lead programs, Voriconazole Inhalation Powder, the first clinical study ever in healthy subjects of a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation, and Tacrolimus Inhalation Powder for use in solid organ transplants, despite a challenging clinical trial environment due to the Covid-19 pandemic.”

“And importantly, this quarter we’ve further validated the broad potential of our Thin Film Freezing platform technology, in ways we might not have imagined even just months ago,” said Mattes.

“To help meet the challenge of the global pandemic, our Thin Film Freezing technology has the potential to be able to repurpose and better deliver existing approved drugs that may have therapeutic potential against the SARS-CoV-2 virus,” continued Mattes. “We are actively engaged with several leading research institutions, as well as a number of biopharmaceutical companies, to study the incorporation of our technology with vaccines and anti-virals with the goal of providing more effective real-world delivery capabilities. And today, we are announcing an initial collaboration with one of the country’s industry leaders, PLUS Products, Inc. to develop an entirely new delivery modality for cannabinoid products using our TFF technology.”

“We believe TFF Pharmaceutical’s unique ability to rapidly investigate, prototype and develop a wide variety of compounds using our technology allows us to be nimble in responding to market conditions and to be able to take advantage of opportunities as they arise,” concluded Mattes.

Conference Call and Webcast Information

The Company will host a conference call today, Thursday, May 14, 2020, at 5:00 pm, Eastern Daylight Time, to review the clinical, corporate and financial highlights. To participate in the conference call, please dial the following numbers prior to the start of the call:

U.S. Dial-In Number: Toll-Free: (800) 816-3024

International Dial-In Number (857) 770-0106

Conference ID: 7287036

The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://edge.media-server.com/mmc/p/rwrfx2up. Please access the Company’s website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company’s website in the Events Calendar of the Investors section.

Recent Clinical and Corporate Highlights:

• Voriconazole Inhalation Powder: TFF’s lead clinical program, Voriconazole Inhalation Powder, to treat the severe and life-threatening disease of Invasive Pulmonary Aspergillosis, or IPA, successfully completed all four dosing cohorts in the single ascending dose (SAD) phase of the trial, and is progressing in the multiple ascending dose (MAD) portion of the study even in the midst of the Covid pandemic. We expect Phase 1 SAD/MAD dosing to be completed by mid-July, with topline results reported in September of this year.

• Tacrolimus Inhalation Powder: TFF’s second clinical program, Tacrolimus Inhalation Powder, is an inhaled dry powder version of tacrolimus, one of the most commonly administered immunosuppressive drug used in solid organ transplants. The Company intended to begin Single Ascending Dose Phase I studies by the end of Q1-2020 in Australia, with Multiple Ascending Dose studies beginning in Q2-2020. However, with the spread of COVID-19 across the Australian continent, the Company’s CRO partner informed us there would be a delay in initiating the trial. The trial has been approved by Australian regulatory authorities and dosing will proceed once the risk to the subjects from COVID-19 has been sufficiently addressed. We note that the per capita coronavirus infection rates are low in Australia and testing is being expanded to the general population. We anticipate being able to start the trial by the end of June of this year.

• License agreement for use of TFF technology in the cannabis market
  
  TFF has sublicensed its Thin Film Freezing technology on an interim basis to an unaffiliated third-party, who will in turn work with PLUS Products, Inc., one of the country’s market leaders, to develop and commercialize non-therapeutic cannabis and cannabis-derived products, including cannabidiol (CBD). Subject to PLUS’ development and evaluation of their cannabis and cannabis-derived products, TFF Pharmaceuticals expects to sign a Long-term License Agreement, pursuant to which TFF Pharmaceuticals expects to receive licensing fees, along with future product sale royalties. TFF believes its Thin Film Freezing technology has the potential of being a new delivery modality for these products as a consumer friendly, alternative to vaping and combustion delivery methods.

• Strategic Business Development and Partnership Activities – Research and Defense Contracting Agencies: During the quarter, TFF Pharmaceuticals entered into a research collaboration with the University of Georgia’s Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity and efficacy of universal influenza vaccines following Thin Film Freezing. Researchers in the University of Georgia’s CVI are world-leaders in vaccine development. Under the terms of the collaboration, TFF Pharmaceuticals, along with UT Austin and the University of Georgia’s CVI, will collaborate to investigate TFF-formulated CVI recombinant universal influenza vaccines with the goal of eliciting broadly reactive immune responses and potentially providing longer-lasting protection against a wider variety of influenza viruses, in a pre-clinical challenge model.

Also during the quarter, TFF entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the U.S Army’s premier institution and facility for defensive research into countermeasures against biological warfare. TFF and USAMRIID will collaborate over a 3-year period to investigate Thin Film Freezing to formulate two different countermeasures, a monoclonal antibody against Alphaviruses (e.g. Venezuelan, Western, and Eastern equine encephalitis viruses) and a vesicular stomatitis virus vaccine against Filoviruses (e.g. Ebola, Marburg). USAMRIID will evaluate the immune responses induced by the dry powder formulations given by the pulmonary or intranasal route in a rodent model, as compared to the traditional routes of administration.

We are also actively engaged in a number of material transfer agreements and work projects with potential partners to evaluate our Thin Film Freezing platform with both large and small molecules, New Chemical Entities, vaccines and other exciting opportunities.

• COVID-19/ SARS-CoV-2 Drug Repurposing Feasibility Projects: TFF is actively reviewing previously FDA approved drugs that may be repurposed in an effort to combat the novel coronavirus behind the COVID-19 pandemic outbreak. The Company is reviewing libraries of compounds that could potentially benefit from the characteristics of the TFF technology in developing a dry powder product delivered directly to the lung that is capable of targeting SARS-CoV-2 and potentially similar viruses such as SARS-CoV, MERS-CoV and other endemic coronaviruses.

During the quarter, the Company and the inventor of its TFF technology, Dr. Robert O. (Bill) Williams III, focused on the existing antiviral drug, niclosamide, to enhance its effect as a potential COVID-19 therapy. Niclosamide is an FDA-approved oral anthelminthic drug that we believe has the potential to be repurposed to treat a variety of viral infections, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), Zika virus (ZIKV), and others. Our Thin Film Freezing technology is being evaluated to develop an inhaled form of niclosamide that could potentially enhance this promising drug’s bioavailability for treating respiratory modes of infection. If successful, TFF Pharmaceuticals would potentially progress to filing an IND for this compound with the FDA.

Financial Results

For the three months ended March 31, 2020, compared to the prior year

• Research and Development (R&D) expenses: R&D expenses for the first quarter of 2020 were $2.2 million, compared to $1.7 million for the same period in 2019.
• General & Administrative (G&A) expenses: G&A expenses for the first quarter of 2020 were $1.6 million, compared to $532,000 for the same period of 2019.
• Net Loss: TFF Pharmaceuticals reported a net loss for the first quarter of 2020 of $3.8 million, compared to a net loss of $2.2 million for the same period of 2019.

About TFF Pharmaceuticals’ Thin Film Freezing technology platform

TFF Pharmaceuticals’ Thin Film Freezing (TFF) platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine. The TFF process results in a “Brittle Matrix Particle,” which possesses low bulk density, high surface area, and typically an amorphous morphology. allowing the particles to supersaturate when contacting the target site, such as lung tissue. Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75 percent.

About TFF Pharmaceuticals

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 41 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.

SAFE HARBOR

This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the benefits of the Company’s TFF platform and its dry powder versions of Voriconazole and Tacrolimus and the Company’s plans to add to its existing pipeline of product candidates and license its technology to PLUS Products and third-parties. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (ii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iii) the risk that the Company will not be able to conclude a long-term commercial agreement with PLUS Products or any other third-party, (iv) the legal and regulatory risks associated with cannabis-based products and (v) those other risks disclosed in the section “Risk Factors” included in the Company’s 2019 Annual Report on Form 10-K filed with the SEC on March 26, 2020. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

TFF PHARMACEUTICALS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
		Three Months Ended March 31, 2020			Three Months Ended March 31, 2019
Operating expenses
Research and development	$	2,235,542		$	1,670,862
General and administrative		1,617,924			531,598
Total operating expenses		3,853,466			2,202,460
Loss from operations		(3,853,466	)		(2,202,460	)
Other income
Interest income		56,268			19,645
Total other income		56,268			19,645
Net loss		(3,797,198	)		(2,182,815	)
Preferred stock dividend		—			(221,278	)
Net loss applicable to common stockholders	$	(3,797,198	)	$	(2,404,093	)
Net loss applicable to common stock per share, basic and diluted	$	(0.20	)	$	(0.55	)
Weighted average common shares outstanding, basic and diluted		19,008,611			4,400,000

TFF PHARMACEUTICALS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS
		As of March 31, 2020				As of December 31, 2019
Assets			(Unaudited)
Current Assets
Cash and cash equivalents		$	25,731,010			$	28,094,936
Prepaid assets and other current assets			859,064				1,092,462
Total Assets		$	26,590,074			$	29,187,398
Liabilities and Stockholders’ Equity
Current Liabilities
Accounts payable		$	1,204,952			$	410,638
Total Current Liabilities			1,204,952				410,638
Accrued research and development expense			—				1,132,013
Total Liabilities			1,204,952				1,542,651
Stockholders’ Equity:
Common stock, $0.001 par value, 45,000,000 shares authorized; 18,671,658 and 18,450,992 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively			18,672				18,451
Additional paid-in capital			44,896,346				43,338,710
Accumulated other comprehensive loss			(20,283	)			—
Accumulated deficit			(19,509,612	)			(15,712,414)	)
Total Stockholders’ Equity			25,385,123				27,644,747	)
Total Liabilities and Stockholders’ Equity		$	26,590,074			$	29,187,398